Evidence map›Paper›PMID 39894709›Full record

ArticleClinical lung cancer2025

POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database Analysis.

Matthew S Lara, Jonathan W Riess, Guneet Kaleka, Alexander Borowsky, John D McPherson, Luis A Godoy, Lorenzo Grego, Primo N Lara, Nicholas Mitsiades

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matthew S LaraARC-MD Program, UC Davis School of Medicine, Sacramento, CA.
Jonathan W RiessDavis Comprehensive Cancer Center, University of California (UC), Sacramento, CA.
Guneet KalekaDavis Comprehensive Cancer Center, University of California (UC), Sacramento, CA.
Alexander BorowskyDavis Comprehensive Cancer Center, University of California (UC), Sacramento, CA.
John D McPhersonDavis Comprehensive Cancer Center, University of California (UC), Sacramento, CA.
Luis A GodoyDavis Comprehensive Cancer Center, University of California (UC), Sacramento, CA.
Lorenzo GregoTempus Inc, Chicago, IL.
Primo N LaraDavis Comprehensive Cancer Center, University of California (UC), Sacramento, CA.
Nicholas MitsiadesDavis Comprehensive Cancer Center, University of California (UC), Sacramento, CA. Electronic address: nmitsiades@ucdavis.edu.

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
NCI NIH HHS P30 CA093373
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GenomicsImmunotherapyLung CancerNext Generation SequencingPOLE

Identifiers

PMID39894709
PMCPMC12230208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.